Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-PH + Pyrotinib vs TCbHP in HER2+ Breast Cancer
NCT05918328Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, sponsored by Henan Cancer Hospital. Started May 2023; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05918328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918328.